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The use of biomarkers of environmental exposure to explore new risk factors for pancreatic 
cancer presents clinical, logistic, and methodological challenges that may also be relevant in 
research on other complex diseases.  
Objectives. 
First, to summarize the main design features of a prospective case-control study –nested within 
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort– on plasma 
concentrations of persistent organic pollutants (POPs) and pancreatic cancer risk. And second, 
to assess the main methodological challenges posed by associations among characteristics and 
habits of study participants, fasting status, time from blood draw to cancer diagnosis, disease 
progression bias, basis of cancer diagnosis, and plasma concentrations of lipids and POPs. 
Results from etiologic analyses on POPs and pancreatic cancer risk, and other analyses, will be 
reported in future articles. 
Methods. 
Study subjects were 1,533 participants (513 cases and 1,020 controls matched by study centre, 
sex, age at blood collection, date and time of blood collection, and fasting status) enrolled 
between 1992 and 2000. Plasma concentrations of 22 POPs were measured by gas 
chromatography - triple quadrupole mass spectrometry (GC-MS/MS). To estimate the 
magnitude of the associations we calculated multivariate-adjusted odds ratios by unconditional 
logistic regression, and adjusted geometric means by General Linear Regression Models. 
 
Results. 
There were differences among countries in subjects’ characteristics (as age, gender, smoking, 
lipid and POP concentrations), and in study characteristics (as time from blood collection to 
index date, year of last follow-up, length of follow-up, basis of cancer diagnosis, and fasting 
status). Adjusting for centre and time of blood collection, no factors were significantly associated 
with fasting status. Plasma concentrations of lipids were related to age, body mass index, 
fasting, country, and smoking. We detected and quantified 16 of the 22 POPs in more than 90% 
of individuals. All 22 POPs were detected in some participants, and the smallest number of 
POPs detected in one person was 15 (median, 19) with few differences by country. The highest 
concentrations were found for p,p’-DDE, PCBs 153 and 180 (median concentration: 3371, 1023, 
and 810 pg/mL, respectively). We assessed the possible occurrence of disease progression 
bias (DPB) in eight situations defined by lipid and POP measurements, on one hand, and by 
four factors: interval from blood draw to index date, tumour subsite, tumour stage, and grade of 
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The coexistence of differences across study centres in some design features and participant 
characteristics is of relevance to other multicentre environmental studies. Relationships among 
subjects’ characteristics and among such characteristics and design features may play 
important roles in the forthcoming analyses on the association between plasma concentrations 






BMI, body mass index; CI, confidence interval; DAG, Directed Acyclic Graph; DPB, disease 
progression bias; p,p’-DDE, dichlorodiphenyldichloroethene; p,p’-DDT, 
dichlorodiphenyltrichloroethane; EPIC, European Prospective Investigation into Cancer and 
Nutrition; HCB, hexachlorobenzene; HCH, hexachlorocyclohexane; PBDE, polybrominated 
diphenyl ethers; PCBs, polychlorinated biphenyls; PeCB, pentachlorobenzene; POPs, 
persistent organic pollutants. 
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Advancing knowledge on environmental causes of pancreatic cancer remains elusive (Amaral 
et al., 2012; Antwi et al., 2015; Barone et al., 2016; Kamisawa et al., 2016; Porta, 2001, 2005). 
This might partly be due to the difficulties that such a biologically and clinically aggressive 
disease poses to obtain biological specimens, to use meaningful biomarkers, to elicit accurate 
information from severely ill patients, and sometimes to achieve a precise anatomo-pathological 
diagnosis (Porta, 2001). Yet some of such clinical, logistic, and methodological challenges are 
also common in environmental research on other diseases (Baris et al., 2000; De Roos et al., 
2005; Hoppin et al., 2000; Rylander et al., 2015; Porta et al., 1999; Vo et al., 2008; Wolff et al., 
2000, 2007). Notably, biomarkers of exposure to lipophilic contaminants are prone to disease 
progression bias (DPB), a mechanism of reverse causation bias through which the 
pathophysiological progression of the disease alters body concentrations of the contaminants in 
blood and fatty tissues; as a consequence, disease-altered exposure estimates lack etiologic 
significance (Baris et al., 2000; Hoppin et al., 2000; Porta et al., 1999, 2009b, 2014; Rylander et 
al., 2015). 
 
A different but related issue is the influence of fasting status at blood collection on blood 
concentrations of a variety of lipophilic substances (e.g., some vitamins and other nutrients, 
most organochlorine compounds). Another related and unresolved issue that affects many 
environmental etiologic studies is how to approach conceptually and analytically the 
concomitant confounding and mediating effects of blood lipids, fasting, and body mass index 
when estimating possible causal effects of such lipophilic substances (Donat-Vargas et al., 
2018; Gallo et al., 2011; O'Brien et al., 2016; Rylander et al., 2015). 
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Diseases whose diagnostic accuracy and precision in clinical practice depend on age, gender, 
lifestyle or other factors (López et al., 2014; Porta, 2001, 2005; Porta et al., 1994) offer the 
opportunity to assess whether the diagnostic basis, and the corresponding diagnostic certainty, 
contribute to disease misclassification, and hence to bias causal estimates. 
 
While prospective longitudinal designs as cohort-nested case-control studies can overcome 
several of the previously sketched difficulties, control of biases associated with disease 
progression cannot rest exclusively on such studies (Dorgan et al., 1999; Hunter et al., 1997; 
Lee et al., 2014; Porta et al., 2009b; Wolff et al., 1993). 
 
We thought it was necessary and relevant to report on these methodological issues prior to 
analysing data from a cohort-nested case-control study on persistent organic pollutants (POPs) 
and pancreatic cancer risk; results from the etiologic analyses and from other analyses (such as 
predictors of POP concentrations in controls) will be reported in future articles. 
 
Therefore, the objectives of the present report are two-fold: first, to summarize the main design 
features of a prospective case-control study –nested within the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort– on plasma concentrations of POPs and 
pancreatic cancer risk; and second, to assess the main methodological challenges posed by 
potential associations among some characteristics and habits of study participants, fasting 
status, time from blood draw to cancer diagnosis, disease progression bias, basis of cancer 
diagnosis, and plasma concentrations of lipids and POPs. 
 
2. METHODS AND RESULTS 
 
2.1. Study population 
 
We performed a case-control study nested within the European Prospective Investigation into 
Cancer and Nutrition (EPIC) cohort. The EPIC cohort has been previously described in detail 
(Riboli et al., 2002). Briefly, 521,457 subjects (153,447 men) aged 35–70 years old were 
recruited between 1992 and 2000 by 23 collaborating centres from 10 European countries. 
Three bio-repositories from the EPIC study contributed samples for the present study: the 
repository from Denmark, which centralized samples from the collaborating centres of Aarhus 
and Copenhagen; the repository from the collaborating centre of Umeå, in Sweden; and the 
IARC central repository, which centralized the biospecimens of 8 countries (Germany, United 
Kingdom, Netherlands, Italy, Spain, Greece, France, and Norway) (Supplemental Table 1). 
 
Over 98% of the 1,533 participants in the present study (pancreatic cancer cases plus controls) 
were enrolled between 1992 and 1998. They were followed until cancer diagnosis, death, 
migration, or the end of the follow-up period (2007, 2010 and 2014 for Denmark, IARC, and 
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Umeå, respectively), whichever occurred first (Supplemental Table 1). The median duration of 
follow-up for the study participants was 11.6 years (mean, 11.4 y; standard deviation [SD], 3.4 
y). 
 
Pancreatic cancer cases, coded as C25 (C25.0-25.3, 25.7-25.9) according to the International 
Classification of Diseases-Oncology (ICD-O) 3rd edition, were identified and included in the 
study. Exclusion criteria were: a) cases of endocrine pancreatic cancer; b) occurrence of other 
malignant tumours preceding the diagnosis of pancreatic cancer, except for non-melanoma skin 
cancer; c) cases with pancreatic cancer diagnosed during the first 2 years of blood draw (5 
years for cases from Denmark); and d) 12 cases with less than 2 straws of plasma remaining 
available. Thus, 513 cases were included in the present study, of which 135 (26.3%) came from 
Denmark, 79 (15.3%) from Umeå (Sweden), and 299 from the IARC central repository 
(contributing countries: Germany, 13.6% of the 513 cases; United Kingdom, 11.7%; The 
Netherlands, 9.2%; Italy, 8.4%; Spain, 7.2%; Greece, 5.5%; France, 1.6%; and Norway, 1.2%) 
(Supplemental Table 1). 
 
For each case, two control subjects alive and free of cancer at the time of diagnosis of the index 
case were selected using an incidence density sampling procedure (Rothman et al., 2008); only 
6 cases had just one control. Thus, a total of 1020 matched controls were included. Matching 
factors were study centre, sex, age at blood collection (± 1 year), date (± 6 months) and time of 
the day (± 2 h) of blood collection, fasting status (<3 h, 3-6 h, >6 h after last meal), and, for 
women, use of exogenous hormones (yes, no). The age at blood collection of 11 controls 
differed by more than ± 1 year (up to 4.8 years) to the age of their matched case; the date of 
blood collection of 11 controls (4 of the previous) differed by more than ± 6 months (up to 12 
months); and the time of blood collection of 84 controls differed by more than ± 2 h (up to 3.5 h) 
(information on time of blood collection was missing for 179 individuals from Umeå and for 27 
individuals of 9 case sets from IARC repository). The fasting status of 55 controls was different 
from the fasting status of their matched case, and was missing for 21 participants. Finally, use 
of exogenous hormones of 8 controls was different from use of their matched case, and was 
missing for 92 women. 
 
The EPIC study was approved by the Ethical Review Board of the International Agency for 
Research on Cancer (IARC, Lyon) and by the local Ethical Committees. 
 
 
2.2. Main variables, and collection of blood samples 
 
At recruitment a questionnaire collected baseline information about sociodemographic 
characteristics, lifestyles (especially those related to cancer aetiology, such as lifetime history of 
alcohol and tobacco consumption), and medical history. Validated country/centre-specific 
dietary questionnaires were used at baseline for recording average daily intakes over the 
  – 7 – 
previous 12 months. Anthropometric measures and blood samples were taken at recruitment for 
most subjects. Over 80% of participants in the present study underwent blood extraction the 
same day of the recruitment, and 11% during the previous or the following 7 days after 
recruitment; only 3% of participants had their blood collected more than one year after being 
enrolled. 
 
For a subset of pancreatic cancer cases information on characteristics of the tumour was also 
collected. Information on the pancreatic subsite of the tumour was available for 348 of the 513 
cases included in the study (68%). The category ‘overlapping’ of tumour subsite included 
tumours registered as an overlapping lesion of the pancreas (C25.8, N = 18), as localised in a 
pancreatic duct (C25.3, N = 2), and in other specified parts of the pancreas (C25.7, N = 3). 
Information on the stage of the tumour was available for 177 cases (35%) as it was registered 
just in some centres. The EPIC classification for stage of the tumour included: in situ (none), 
localised (N = 51), metastatic (N = 49), metastatic regional (N = 33), and metastatic distant (N = 
44). For the present study, the three last categories were joined in one category named 
‘metastatic’. A minimum of one basis of the cancer diagnosis was recorded for 506 cases 
(98.6%): 50 cases had three bases of cancer diagnosis recorded, 156 cases had two bases, 
and 300 cases had one basis. Only 86 cases (17%, all from IARC bio-repository) had 
information on the grade of the tumour: 11, 45 and 29 cases were classified as well, 




2.3. Statistical analyses 
 
Univariate statistics were computed as customary (Armitage et al., 2002; Kleinbaum et al., 
1998). To assess differences on participants’ characteristics by gender, case-control status, 
fasting status, basis of cancer diagnosis, and concentrations of lipids and persistent organic 
pollutants, Student’s t-test, ANOVA, Kruskal-Wallis, and Mann-Whitney’s U tests were used. 
Fisher’s exact test for homogeneity was applied to assess the relationship between two 
categorical variables. Spearman’s rank correlation coefficient (ρ) was computed to evaluate 
correlations among pairs of POPs. 
 
To estimate the magnitude of the associations between participants’ characteristics and a) 
fasting status, and b) basis of cancer diagnosis, multivariate-adjusted odds ratios (ORs) and 
their corresponding 95% confidence intervals (CI) were calculated by unconditional logistic 
regression (Rothman et al., 2008). The main effects of all predictors were independently 
explored in base models. Final models were selected in accordance with the nature of the 
variables and the study objectives. Thus, final models for fasting status were adjusted for centre 
and time of the day of blood collection, while final models for basis of cancer diagnosis were 
adjusted for age at diagnosis, sex, and centre. 
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General Linear Regression Models (GLM) were applied to study the relationships of 
participants’ characteristics with lipid concentrations (Armitage et al., 2002). GLM were also 
used to study the relation between lipid or POP concentrations in plasma samples collected 
during recruitment and some variables related to the disease, such as the time elapsed 
between blood collection and the date of pancreatic cancer diagnosis, or some characteristics 
of the tumour (among cases with available information). Results are expressed as adjusted 
geometric means (aGMs) with the corresponding 95% CIs. The Kolmogorov-Smirnov test for 
normality was used to check the distributions of lipid and POP concentrations, and of the time 
between blood collection and cancer diagnosis; as none was normal, log-transformed values 
were used in regression analyses. The following potential confounders were included in the final 
models: age, sex, body mass index (BMI), fasting status, and centre (repository in models 
including tumour characteristics). 
 
We assessed associations between plasma concentrations of POPs and study and participant 
characteristics. POP concentrations were entered in the models as quartile categories (defined 
using the concentrations in controls). 
 
To assess exposure to multiple compounds, we computed a) the sum of PCBs for each 
participant by adding plasma concentrations of all ten PCBs, and then assigning each 
participant to one quartile of the new variable (sum of PCBs) (Porta et al., 2012); b) the sum of 4 
PCBs for each participant by adding plasma concentrations of 4 prevalent PCBs (congeners 
118, 138, 153, and 180), and then assigning each participant to one quartile of the new variable 
(sum of 4 PCBs); and c) to compute the sum of orders of the 6 most prevalent organochlorine 
pesticides, each compound was categorized in quartiles and the category number of each 
compound was summed, producing a value ranging between 6 (when concentrations of all 6 
organochlorine pesticides were in the lowest quartile) and 24 (when concentrations of all 6 
compounds were in the top quartile) (Gasull et al., 2012, 2018; Porta et al., 2012). Other options 
were also considered; because results were similar to the three variables above, the latter were 
chosen for presentation. 
 
For the 16 compounds quantified in more than 90% of individuals (see below) we calculated the 
number of POPs detected in each person at high concentrations (nPhc) as follows: for each 
subject we added the number of POPs whose plasma concentrations were equal to or greater 
than a selected cut-off point, as percentile 90 (P90) (the upper decile), or percentile 75 (P75) 
(the upper quartile) (Porta et al., 2012; Pumarega et al., 2016). 
 
Based on historical factors related to exposure to POPs (essentially, before and after World War 
II) (Nøst et al., 2017; Porta et al., 2008b; Rylander et al., 2015), the following birth cohorts were 
defined: participants born from 1919 to 1938 (N = 817), from 1939 to 1945 (N = 503), and from 
1946 to 1964 (N = 213). 
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The level of statistical significance was set at 0.05 and all tests were two tailed. Analyses were 
conducted using SPSS version 18 (SPSS, Armonk, NY, USA, 2009) and R version 3.1.3 (R 
Core Team, Vienna, Austria, 2015). 
 
 
2.4. Baseline characteristics of study participants  
 
At blood collection, the age of the 1,533 individuals included in the study ranged between 29 
and 76 years (mean, 56.8 years). Over 58% of participants had overweight or obesity, 26% 
were current smokers, and 28% consumed more than 18 g of alcohol per day (Table 1). 
 
Differences in baseline characteristics were observed by country (Supplemental Table 1). The 
percentage of women was significantly lower in Denmark (38%) and Germany (37%), and 
higher in the United Kingdom (65%) and The Netherlands (79%), while in France and Norway 
all participants were women (N = 24 and 18, respectively). Denmark had the highest proportion 
of current smokers (36%), followed by Italy (34%). 
 
Participants from the collaborating centre of Umeå (Sweden) were younger at blood collection 
and had a lower BMI than participants from Denmark and the IARC central repository. As 
mentioned, the end of the follow-up period for participants from Umeå was in 2014, while for the 
rest of centres follow-up ended at least 4 years earlier (2010), and up to 9 years earlier (2005 in 
France). However, the period of blood collection in Umeå (1992-1996) was similar to the other 
centres. The age at cancer diagnosis of cases from Umeå (mean = 65.4 ± 8.7 years old) was 
similar to that of cases from the other centres (mean = 65.8 ± 7.6), as expected (Supplemental 
Table 1). For cases, the index date was the date of cancer diagnosis; for controls, the index 
date was the date of cancer diagnosis of the case they were matched with. 
 
As a result, participants from Umeå:  
a) had the longest follow-up (they may have been followed for up to 22 years, from 1992 to 
2014), and the mean follow-up for Umeå was 15.3 years, while for the rest of centres it was 
10.7 years; 
b) had the longest time from blood collection to index date: mean of 12.5 years for Umeå, and 
8.3 for the other centres; and  
c) were younger at blood collection: mean of 52.9 years for participants from Umeå, and 57.5 
for the other centres (Supplemental Table 1). 
 
The above results are of potential relevance if the pancreatic cancer risk function was not linear 
over measures of time or age; e.g., if risks associated with certain exposures or subject 
characteristics were essentially or only apparent after 10 years since blood collection, then the 
characteristics of the study in Umeå would have a stronger influence in the detection of such 
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risks than the other countries. As we shall see later, there were also other differences by study 
centre. 
 
The distribution of the time from blood collection to index date is shown in Figure 1. It was 
between 2 and <5 years for 14% of participants, between 5 and <10 years for 51% of 
participants, and ≥10 years for 35%. As mentioned, we included no cases (and thus no matched 
controls) with a diagnosis of pancreatic cancer within <2 years of blood draw. Only 5% of 
participants, all from Umeå, had such time interval ≥15 years. In multivariate models (for cases 
and for controls separately), repository was the only study characteristic statistically significantly 
associated with time from blood collection to index date, adjusting for age, sex, and BMI; the 
minor exception were overweight and obese controls, who had slightly longer intervals than 
normal weight controls: the aGM of the time from blood collection to index date (adjusted for 
age, sex, and centre) for obese controls was 8.7 years, 95% CI: 8.3-9.3 whereas the 
corresponding aGM for normal weight controls was 7.8 years, 95% CI: 7.5-8.1 (p-value = 
0.008). The relationship among cases was the opposite than among controls: aGM for obese 
cases = 7.6 years, 95% CI: 6.9-8.4 and the aGM for normal weight cases = 8.3 years, 95% CI: 
7.8-8.8 (p-value = 0.150). No other associations were observed either when subjects from 
Umeå were excluded. 
 
 
2.5. Baseline characteristics of cases and controls  
 
As expected, cases and controls showed no differences in the variables they were matched by. 
No differences between cases and controls were observed either for BMI, education, marital 
status, alcohol consumption, or physical activity (Table 1). In contrast, a higher proportion of 
cases than controls were current smokers at study entry (33% vs. 23%, respectively), and had 
diabetes mellitus (6% of cases vs. 3% of controls), as expected. 
 
 
2.6. Basis of cancer diagnosis 
 
We next assessed whether the diagnostic basis of the pancreatic cancer, and its corresponding 
potential disease misclassification, were independent or instead associated with 
sociodemographic, lifestyle and clinical characteristics of cases. Of the 506 cases (98.6% of all 
513 cases) with information on the basis of cancer diagnosis, 382 (75.5%) were microscopically 
confirmed, while the remaining 124 (24.5%) were diagnosed by imaging results, laboratory 
tests, clinical symptoms, or physical examination (Table 2). 
 
Significant differences in the percentage of cases with microscopic confirmation were observed 
across countries: more than 95% of cases from Denmark and Umeå were microscopically 
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confirmed, while this figure was 39% in Greece, and 22% in the United Kingdom (Supplemental 
Table 1). 
 
Microscopic confirmation was higher in men than in women (83% and 68%, respectively). As 
expected and important, it was lower at older ages: it was about 83% in cases <60 years old, 
78% in cases 60-69 years, and 68% in cases ≥70 years (Table 2). Microscopic confirmation was 
not related to subsite or stage of the tumour, neither to BMI. By contrast, in univariate analyses 
it was associated with smoking, alcohol, and physical activity. In models adjusting for age, sex 
and centre, only differences by age remained statistically significant. There was also a positive, 
monotonic, but statistically non-significant relation between education and microscopic 
confirmation. Age was a strong confounder of some associations with diagnostic basis. For 
instance, 82% of current smokers and 72% of never smokers had been diagnosed by 
microscopic methods; however, since current smokers were younger than never smokers (e.g., 
49% vs. 34% were <55 years old, respectively), when adjusting for age the observed relation 
between smoking and diagnostic basis became much weaker (Table 2). 
 
 
2.7. Fasting status 
 
In descriptive analyses, differences in fasting status were observed for sex, age, study centre, 
time of the day of blood collection, smoking status, alcohol consumption, and physical activity. 
Fasting status was one of the variables displaying larger differences across study centres and 
countries: while a large proportion of participants from Umeå, Italy and Spain had been fasting 
for more than six hours (94%, 83% and 68%, respectively), the corresponding percentage for 
the rest of countries was <15% (except France, with 7 out of its 24 participants with >6 hours of 
fasting) (Supplemental Table 1). Time of blood collection was strongly associated with fasting: 
chances of having fasted >6 hours decreased with time from early morning to late afternoon. In 
Umeå over 70% of participants (165 out of 235) had been fasting for >6 hours and did not have 
the time of blood collection registered. 
 
Adjusting for centre and time of blood collection, sex, age, BMI, smoking, alcohol intake or 
physical activity were not significantly associated with fasting status (Table 3). As expected, no 




2.8. Lipid concentrations in plasma 
 
Measurements of total cholesterol and triglycerides were carried out enzymatically by Abbott 
Architect reagents (Abbott Laboratories, Abbott Park, IL, USA) in plasma obtained at study entry 
(Riboli et al., 2002). Analyses were performed at the National Institute for Health and Welfare 
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(THL), Finland. A 400 µL straw with plasma was sent from the biorepositories to THL for lipid 
and POP analyses (see also below). Total lipids (TL) were calculated by the Standard formula 
2, based on total cholesterol and triglycerides (Bernert et al., 2007; Phillips et al., 1989; Porta et 
al., 2009a). 
 
There were no significant associations between lipid concentrations (total cholesterol, 
triglycerides, and TL) and case-control status (Figure 2 and Supplemental Table 2). The 
absence of association between lipids and case-control status was also evident when adjusting 
for age, sex, centre, BMI and fasting status (p-value = 0.441) (Table 4). Although these findings 
could be expected because of the study design (i.e., because blood samples were obtained at 
least 2 years before cancer diagnosis), it was methodologically warranted to confirm them. 
 
Total lipids tended to be significantly higher in subjects with higher age and BMI. Men also had 
slightly higher values than women (Supplemental Table 2). Except for sex, these relationships 
held when models were mutually adjusted for age, sex, centre, BMI, and fasting status (p-
values ≤ 0.036) (Table 4). A statistically significant association was also observed between lipid 
concentrations and smoking status in adjusted models: participants who reported to be current 
smokers had higher concentrations of triglycerides and TL (Table 4 and Supplemental Table 3). 
Adjusted models also show that triglycerides and TL were associated with fasting status: 
individuals with more than 6 hours of fasting had lower concentrations of triglycerides and of TL. 
 
Differences in lipid concentrations were also observed by country: while participants from Umeå 
(Sweden) were younger, had a lower BMI, and were more often fasting (Supplemental Table 1), 
they had the highest mean and median concentrations of total cholesterol and total lipids 
(Supplemental Table 2); participants from Umeå also showed the highest concentrations of 
triglycerides after adjusting for age, sex, BMI and fasting status (Table 4 and Supplemental 
Table 3). In adjusted models, the lowest concentrations of TL were observed in participants 
from Spain and Greece: the aGM of TL was 736 mg/dL, 585 mg/dL and 587 mg/dL for subjects 
from Umeå, Spain and Greece, respectively (Table 4). 
 
 
2.9. Concentrations of persistent organic pollutants (POPs) 
 
2.9.1. Chemical analyses of POP concentrations  
POP concentrations were measured in 200 µL plasma samples from the same blood collection 
sample obtained at study entry in which lipids were measured (Riboli et al., 2002). Analyses 
were performed at THL (Koponen et al., 2013). Twenty-two POPs were measured: three 
polybrominated diphenyl ethers (PBDEs 47, 99, 153), eight non-dioxin like polychlorinated 
biphenyls (PCB congeners 74, 99, 138, 153, 170, 180, 183, and 187), two dioxin like PCBs 
(congeners 118 and 156), and nine organochlorine pesticides or their metabolites: 
dichlorodiphenyltrichloroethane (p,p’-DDT), dichlorodiphenyldichloroethene (p,p’-DDE), α-
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hexachlorocyclohexane (α-HCH), β-HCH, γ-HCH, pentachlorobenzene (PeCB), 
hexachlorobenzene (HCB), trans-nonachlor, and oxychlordane. 
 
Pretreatment of the samples was as follows: ethanol and 13C-labelled internal standards of each 
compound in toluene were added to samples (200 µL) in test tubes and thoroughly mixed to 
precipitate the proteins and equilibrate internal standards. Dichloromethane-hexane (1:4) was 
added for extraction followed by activated silica to bind the sample water, ethanol, and 
precipitate. Samples were mixed, and layers were allowed to separate. The upper 
dichloromethane-hexane layer was poured to a solid phase extraction cartridge (SPE cartridge) 
containing from bottom to top 10% AgNO3 impregmented silica and a mixture of Na2SO4 and 
silica. The lower layer in the test tube was extracted again with dichloromethane-hexane, which 
was also poured to SPE-cartridge. Elution of SPE-cartridges was continued with 
dichloromethane-hexane, and the eluate was concentrated to 15-20 µL for gas chromatography 
- triple quadrupole mass spectrometry (GC-MS/MS) analysis. The instrument used was an 
Agilent 7010 GC-MS/MS system (Wilmington, DE, USA), GC column DB-5MS UI (J&W 
Scientific, 20m, ID 0.18 mm, 0.18 μm). Limits of detection ranged from 2 pg/mL for PCB 
congeners and trans-nonachlor to 16 pg/mL for p,p’-DDE. Limits of quantification ranged from 5 
pg/mL for PCB congeners and trans-nonachlor to 40 pg/mL for p,p’-DDE (Supplemental Table 
4). When a sample had a concentration of a compound below the detection threshold, it was 
assigned the mid-value of this limit; when a compound was detected but under the 
quantification threshold, the mid-value between detection and quantification limits was used. 
The THL laboratory participates three times a year in AMAP interlaboratory comparisons (Ring 
Test for Persistent Organic Pollutants in human serum, National Institute of Public Health, 
Quebec, Canada) (Koponen et al., 2013; Krauskopf et al., 2017; Vafeiadi et al., 2017). POP 
concentrations were individually converted to lipid-based concentrations (i.e., corrected or 
normalized for TL) by dividing the crude plasma POP concentration by TL (see ‘Lipid 
concentrations’ above). 
 
The results that follow refer to the entire study population of cases and controls. The results 
were selected for inclusion in the present article based on their importance for the primary study 
on POPs and pancreatic cancer, and on the methodological challenges that the associations 
among POP concentrations, lipid concentrations, and other study variables and features pose 
for the primary study and for other studies on POPs and cancer aetiology. Therefore, as 
mentioned above, the sections below do not include results on POPs and pancreatic cancer 
risk; they also do not include results on all determinants of POP and lipid concentrations in 
plasma in the study subjects. 
 
2.9.2. Percentages of detection and quantification 
We detected and quantified 16 of the 22 compounds (henceforth, ‘most prevalent POPs’) in 
more than 90% of individuals (Figure 3, Table 5, and Supplemental Table 4). Seven of the 10 
PCBs, as well as HCB and trans-nonachlor were detected and quantified in 100% of 
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participants. α-HCH and PeCB were detected in more than 80% of participants and quantified in 
49% and 35%, respectively. The percentage of detection for the other 4 compounds (γ-HCH, 
and PBDEs 47, 99 and 153) ranged between 8% and 47%. Thus, all 22 POPs were detected in 
some participants, and no individual was free from POPs: the smallest number of POPs 
detected in one person was 15. The median number of POPs detected per person was 19, with 
no differences by subjects’ individual characteristics, and very few by country: only Umeå in 
Sweden, and the United Kingdom had medians of 18 and 20 POPs detected per person, 
respectively. Twenty or more compounds were detected in 25% of participants; this was so in 
28% of participants born in 1919–1938 and in 21% of subjects born in 1939–1964. The number 
of POPs quantified per person ranged between 21 and 11, and only 6% of participants had less 
than 16 compounds quantified. 
 
2.9.3. Correlations among POPs 
The highest Spearman’s correlation coefficients (ρ) among crude or wet weight concentrations 
of the 16 most detected POPs were observed between pairs of PCBs; e.g., the ρ between PCB 
170 and 180 was 0.985, and between PCB 138 and 153 it was 0.981). The ρ between 
oxychlordane and trans-nonachlor was 0.809. The ρ between p,p’-DDT and p,p’-DDE was 
0.800, and between HCB and β-HCH, 0.744. The rest of correlations between pairs of 
organochlorine pesticides ranged from 0.159 (for β-HCH and trans-nonachlor) to 0.711 (for p,p’-
DDT and β-HCH) (all p-values <0.001). Finally, correlation coefficients between PCBs and 
organochlorine pesticides ranged from 0.017 (for PCB 156 and β-HCH, p-value = 0.496) to 
0.616 (for PCB 74 and oxychlordane, p-value < 0.001). When TL-corrected concentrations of 
POPs were analysed, ρ’s were only slightly attenuated, and the results just mentioned remained 
virtually unaltered. 
 
2.9.4. Concentrations of POPs 
The highest concentrations were found for p,p’-DDE, PCBs 153 and 180 (median concentration: 
3371, 1023, and 810 pg/mL, respectively). For the rest of PCBs median concentrations ranged 
from 66 pg/mL for PCB 74 to 635 pg/mL for PCB 138; and for the rest of organochlorine 
pesticides the corresponding values ranged from 55 pg/mL for oxychlordane to 393 pg/mL for 
HCB (Table 5). 39% of participants had one or more of the 16 most prevalent POPs at 
concentrations above their respective P90 (i.e., 61% of participants had each of the 16 POPs at 
concentrations below their respective P90). The corresponding figures for P75 were 69% and 
31%. Figures were similar for TL-corrected POPs (e.g., 42% of participants had one or more of 
the 16 TL-corrected POPs above their respective P90). For both cut-offs (P90 and P75), the 
geometric means of the nPhc were 2.9 and 4.3, respectively (2.8 and 4.3 for TL-corrected 
POPs). 
 
Women had statistically significant higher concentrations of HCB (median 29% higher than 
men’s) and β-HCH (median 49% higher), while men had higher concentrations of trans-
nonachlor (median 34% higher than women’s) and of PCBs (except PCBs 74 and 118) (Table 
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5). No significant differences between men and women were observed for p,p’-DDT, p,p’-DDE 
and oxychlordane. In univariate analyses differences in POP concentrations according to age, 
BMI, fasting status, and country were also observed. 
 
Median POP concentrations were higher in subjects with greater age and BMI; e.g., median 
concentrations of HCB were 1.7 times higher in the oldest group than in the youngest, and 2.5 
times higher in obese participants than in normal-weight individuals (Table 5). However, as 
often reported in the literature (Gasull et al., 2012; Porta et al., 2008b), obese participants had 
lower concentrations of some PCBs (congeners 153, 156, 170, and 180) than overweight and 
normal-weight participants. Differences in POP concentrations were also observed by fasting 
status; higher median concentrations were found in individuals who had fasted more than six 
hours. Differences observed by sex, age, BMI and fasting status remained significant when 
POP concentrations were corrected by TL (Supplemental Table 5). 
 
Participants from Spain had the highest concentrations of p,p’-DDT, HCB, β-HCH and PCBs 
183 and 187; remarkably, their median concentration of HCB (4401 pg/mL) was more than 18 
times higher than the corresponding value of participants from the United Kingdom, the country 
with the lowest concentrations of HCB (237 pg/mL); it was also two times higher than the 
corresponding value from the second country with the highest concentrations of HCB (Greece, 
2187 pg/mL) (Table 5). Subjects from Italy had the highest median concentrations of 
oxychlordane, and of PCBs 74, 99 and 118. Germany had the highest concentrations of PCBs 
153, 156, 170, and 180. The highest plasma levels of trans-nonachlor and PCB 138 were found 
in participants from Umeå. Subjects from Greece had the highest concentrations of p,p’-DDE, 
but also the lowest concentrations of all PCBs. The lowest concentrations of p,p’-DDT and p,p’-
DDE were detected in participants from Denmark. Again, similar results were obtained when TL-
corrected POP concentrations were analysed (Supplemental Table 5): the highest 
concentrations (in ng/g of lipid) of p,p’-DDT, HCB, β-HCH and PCBs 180, 183 and 187 were 
observed in subjects from Spain, while participants from Germany had the highest 
concentrations of PCBs 138, 153, 156 and 170. 
 
2.9.5. Relation between lipid and POP concentrations  
Spearman’s correlation coefficients (ρ) among crude concentrations of POPs and the three lipid 
measures (total cholesterol, triglycerides and TL) were all positive and statistically significant; 
the highest values of ρ were 0.464 for oxychlordane and TL, 0.447 for trans-nonachlor and TL, 
and 0.412 for trans-nonachlor and triglycerides (p-values < 0.001). When models adjusting for 
age, sex, centre, and BMI were applied, the observed associations remained significant, with no 
differences according to fasting status. However, most associations between lipid and POP 
concentrations disappeared when concentrations of POPs corrected by TL were used; only 
oxychlordane and trans-nonachlor remained positively and statistically significantly associated 
with triglycerides and TL in adjusted models, mainly in participants with less than six hours of 
fasting. 
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2.10. Disease progression bias 
 
The design of the present study (a prospective case–control nested within a cohort) is a valid 
and efficient way to cope with possible biases caused by changes in lipophilic biomarkers of 
exposure induced by the disease (subclinical or clinical disease); i.e., disease progression bias 
(DPB) (Lee et al., 2014; Porta et al., 2005, 2008a, 2009b, 2014). Moreover, to further control for 
potential DPB, we did not include in the study cases of pancreatic cancer diagnosed within 2 
years of blood draw (5 years for cases from Denmark). Nevertheless, the effectiveness of such 
design features to control DPB has seldom been empirically tested. Furthermore, it is unknown 
whether DPB could operate more than 2 years after blood draw. Therefore, we studied the 
relation between lipid and POP concentrations in plasma samples collected during recruitment, 
and some variables related to the disease. Specifically, we studied: a) the relation between lipid 
concentrations at blood collection and the time elapsed between such collection and the date of 
pancreatic cancer diagnosis (please see section Baseline characteristics of study participants), 
and b) the relation between lipid concentrations and selected characteristics of the tumour, such 
as stage and subsite within the pancreas, and tumour grade (among cases with available 
information). We also analysed the same relationships using POP concentrations instead of 
lipid concentrations. 
 
If subclinical pancreatic cancer or its precursors were increasing concentrations of lipids in 
plasma at the time of blood draw (e.g., through metabolic changes, weight loss and lipid 
mobilization from fatty tissues to blood), we would expect to observe that cases with higher lipid 
concentrations at blood draw (mostly, 5 to 15 years before diagnosis) were diagnosed closer to 
the time of blood draw than cases with lower concentrations of lipids; thus, an inverse 
relationship between lipid concentrations at blood draw and the interval from blood draw to 
cancer diagnosis would suggest the existence of DPB, which would need to be considered in 
the etiologic analyses (e.g., latency analyses stratified by time since blood draw would be 
warranted). 
 
No such inverse association existed between total lipid concentrations of cases and time from 
blood collection to diagnosis, either in descriptive analyses (Figure 4) or in multivariate 
regression models adjusting for study centre, age, sex, BMI, and fasting status (Table 6). No 
inverse associations were observed either for total cholesterol and for triglycerides (results not 
shown). Actually, in multivariate models we observed a slightly positive, non-linear association 
between TL and the time interval (i.e., the opposite of the inverse association suggesting DPB): 
the interval for cases in the upper quartile of TL concentrations was around one year longer 
than for cases in the lowest TL quartile (aGM 8.6 and 7.4, respectively, Table 6). A similar 
positive association was observed when cases with time intervals >15 years and <5 years (only 
registered in Umeå and in the IARC repository, by design) were excluded. When stratifying by 
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fasting status, the positive association between TL and the interval was only observed in non-
fasting individuals (i.e., the less reliable subgroup) (Table 6); there were no associations in 
cases who had fasted ≥3 hours (p-value for interaction = 0.132). Although similar results were 
observed in non-fasting controls, again no statistically significant associations between lipid 
concentrations and the time from blood collection to the index date were observed in controls. 
The positive associations are the opposite of the inverse associations that would suggest DPB 
and thus argue against the occurrence of a DPB. 
 
If subclinical pancreatic cancer or its precursors were increasing concentrations of lipids and, 
thus, of POPs at the time of blood draw, we would expect that cases with higher POPs at blood 
draw would be diagnosed closer to the time of blood draw than cases with lower POPs; thus, an 
inverse relationship between POP concentrations at blood draw and the interval from blood 
draw to cancer diagnosis would suggest the existence of DPB. No such inverse association 
existed for any POP. In fact, in a few instances the association was positive: the interval from 
blood collection to cancer diagnosis was slightly longer in cases with higher concentrations of 
some POPs (both crude and TL-corrected). For instance, cases with TL-corrected 
concentrations of HCB in the upper quartile had such interval more than two years longer than 
cases in the lower quartile once adjusting for study centre, age, sex, BMI, and fasting status 
(aGM of the interval from blood collection to cancer diagnosis for HCB upper and lower 
quartiles: 9.6 and 7.3 years, respectively; p-value = 0.003) (Supplemental Table 6); this 
association remained statistically significant among cases who had fasted ≥3 hours. A similar 
association was found for the sum of PCBs 118, 138, 153 and 180 (aGM for upper quartile = 8.8 
years vs. aGM for the lower quartile = 7.5 years, p-value = 0.025); this association was not 
present in cases who had fasted ≥3 hours (data not shown). No associations were found 
between the mentioned interval and other compounds, such as p,p’-DDT, p,p’-DDE and β-HCH. 
Although attenuated, the interval from blood collection to index date was also slightly longer in 
controls with higher concentrations of some POPs (both crude and TL-corrected). The null 
associations argue against the occurrence of a DPB, and the positive associations are the 
opposite of the inverse associations that would suggest DPB. Aside from reverse causation due 
to DPB (i.e., to disease-increased lipid concentrations), increasing concentrations of POPs over 
time –and, hence a higher concentration of POPs near the time of diagnosis– might also be 
expected if POPs were truly implicated in the development and progression of pancreatic 
cancer. 
 
We also studied the relation between lipid or POP concentrations and some characteristics of 
the tumour and, based on previous work (Porta, 2001; Porta et al., 2007, 2008a, 2009b), we 
hypothesised that if subclinical pancreatic cancer were already causing subtle pathophysiologic 
changes at the time of blood draw (e.g., through moderate weight loss, lipid mobilisation or 
other metabolic changes), we would observe that cases later diagnosed with a more advanced 
disease (e.g., a metastatic tumour) or a more aggressive disease (e.g., a poorly differentiated 
tumour) would have higher lipid and POP concentrations (again, at blood draw). Among the 
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limited number of cases with the available information (see section Main variables, and 
collection of blood samples), tumour stage and pancreatic subsite were not associated with any 
of the three lipid measures (total cholesterol, triglycerides and total lipids, Table 7). These 
results suggest that DPB did not occur. 
 
However, in the 85 cases with data on grading of the tumour and on adjusting variables, 
descriptive and multivariate analyses showed that cases with less differentiated tumours had 
higher concentrations of triglycerides and TL at study entry than cases diagnosed with more 
differentiated tumours (aGM of TL for poorly differentiated tumours = 636 vs. aGM for well 
differentiated tumours = 539; p-value = 0.025) (Table 7). These associations held when cases 
with longer times from blood extraction to cancer diagnosis (e.g., ≥10 years) were excluded. 
These results suggest that DPB might occur. 
 
Similar results for the presence or absence of the associations between all three tumour 
characteristics and the three lipid measures were found when cases in non-fasting status were 
excluded from the analyses. 
 
Finally, lower TL-corrected concentrations of some POPs (as always, at baseline, >2 years prior 
to the diagnosis of pancreatic cancer) were observed in cases with metastatic tumours (N = 
126) than in cases with localised tumours (N = 51), again when adjusting for centre, age, BMI 
and fasting status. Differences were statistically significant only for the sum of PCBs 118, 138, 
153, and 180, and for the sum of all PCBs: aGM of TL-corrected concentrations of all PCBs for 
metastatic tumours = 548 ng/g (95% CI: 503 - 597) vs. aGM for localised tumours = 679 (95% 
CI: 578 - 798) (p-value = 0.050). There were no differences in TL-corrected concentrations of 
POPs by tumour subsite. Contrary to the hypothesis supporting the existence of DPB, TL-
corrected concentrations of POPs were slightly lower in cases with poorly differentiated tumours 
than in cases with moderately differentiated and with well differentiated tumours. These results 
argue against the occurrence of a DPB. 
3. DISCUSSION 
 
We observed a number of associations that may need to be considered in the upcoming 
analyses on the possible influence of POPs on pancreatic cancer risk. Thus, lipid 
concentrations were related to age, BMI, fasting status, country, and smoking; while fasting 
status, once adjusted for centre and time of blood collection, was related to sex and BMI. 
Differences among countries were observed for subjects’ characteristics (as sex, smoking, 
alcohol consumption, physical activity, and diabetes, but not age or BMI), and for study 
characteristics (as year of last follow-up, length of follow-up and, hence, time from blood 
collection to index date, basis of cancer diagnosis, fasting status, and lipid and POP 
concentrations). We found no differences in lipid concentrations between pancreatic cancer 
cases and controls; although expected because of the study design, this fact needed 
confirmation. 
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The fact that lipid concentrations were so similar in cases and controls (Figure 2) shows the 
methodological progress that the present design represents with respect to previous studies on 
POPs and pancreatic cancer risk (Supplemental Tables 7 and 8). Other methodological 
characteristics and findings of previous studies are also summarized in the mentioned Tables. 
 
Adjusted models showed increasing concentrations of total lipids with increasing age and BMI. 
Total lipids were also higher in smokers, in participants with less than six hours of fasting at 
blood collection, and in Umeå. The specific way in which the study was conducted in each 
country determined fasting status.  
 
Therefore, when studying the effects of POP concentrations corrected or normalized by lipids 
(López et al., 2014; Porta et al., 2008a; 2009a), it may be necessary to take into account the 
associations observed between lipid concentrations and age, BMI, fasting status, country, and 
smoking; e.g., because some of the possible effects of these latter variables could partly be 
adjusted by the lipid correction. 
 
Most associations between lipid and POP concentrations waned when concentrations of POPs 
corrected by TL were used, as it can partly be expected from the work of Phillips et al. (Bernert 
et al., 2007; Phillips et al., 1989). 
 
The main traditional reason for the correction of POP concentrations by lipids is to remove 
differences in POP concentrations due to differences in lipid concentrations between fasting and 
non-fasting individuals (Bernert et al., 2007; Phillips et al., 1989; Li et al., 2013).  In the present 
study fasting status was one of the matching factors; thus, lipid correction could be deemed 
unnecessary or unwarranted in conditional or matched analyses (in which, again, fasting status 
is one of the matching factors). However, lipid correction of POP concentrations may be 
preferable than adjusting by fasting if the latter is measured less accurately than plasma 
concentrations of lipids. If uncorrected POP concentrations are used in unconditional analyses, 
then fasting status and BMI may need to be included as covariates. Models with POPs 
uncorrected for lipids (and perhaps unadjusted for BMI as well) may be informative and valid too 
because lipids (and BMI changes) may be both confounders and mediators in the hypothetical 
causal chain between POPs and pancreatic cancer (Donat-Vargas et al., 2018; Gallo et al., 
2011; O'Brien et al., 2016; Rylander et al., 2015). The main relevant causal structures (Hernán 
et al., 2018) are summarized in the Directed Acyclic Graphs (DAGs) shown in Supplemental 
Figure 1. 
 
The specific way in which a study is conducted in each country needs to be considered. For 
instance, more than 90% of participants from Umeå had been fasting for >6 hours and 
information on time of blood collection was less frequently recorded in this centre. Thus, in the 
entire study population the availability of information on time of blood collection was strongly 
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related to fasting status. Furthermore, participants from Umeå were younger, leaner, and had 
higher concentrations of lipids than the average of the rest of participants. 
 
For reasons explained above, we excluded cases diagnosed of pancreatic cancer within 2 years 
of blood draw. We can envision no plausible biases that such exclusion might create in the 
analyses on POPs and pancreatic cancer risk. 
 
We assessed the possible occurrence of DPB in eight situations defined by lipid and POP 
measurements, on one hand, and by four factors: interval from blood draw to date of cancer 
diagnosis, tumour subsite, tumour stage, and grade of differentiation, on the other. In seven of 
the eight situations results argued against the occurrence of a DPB, the possible exception 
being that cases with less differentiated tumours had higher concentrations of triglycerides and 
TL at study entry than cases diagnosed with more differentiated tumours. Analyses of the eight 
situations were possible to different extents due to different numbers of subjects with the 
necessary information available. Several plausible DAGs on DPB in pancreatic cancer have 
previously been proposed for study designs that measure POPs and lipids at the time of 
pancreatic cancer diagnosis (López et al., 2014). 
 
In both pancreatic cancer cases and controls, no inverse association was observed between 
total lipid concentrations and time from blood collection to diagnosis, either in descriptive 
analyses (Figure 4) or in multivariate models. These findings argue against the existence of 
DPB. The available knowledge indicates that the mechanisms of occurrence and progression 
(molecular, genetic and epigenetic) of exocrine pancreatic cancer years before clinical 
emergence of the disease do not entail metabolic and other pathophysiologic changes that alter 
lipophilic biomarkers (Kamisawa et al., 2016). Hence, 5-15 years before diagnosis, subclinical 
pancreatic cancer might be present (e.g., molecular changes) but it is implausible that it would 
already be causing the metabolic and other pathophysiologic changes that we hypothesize 
could bias the results. Nevertheless, current evidence does not rule out that higher 
concentrations of lipids increase risk for pancreatic cancer occurrence or progression (Di 
Ciaula, 2014). And, thus, higher concentrations of lipids near the time of diagnosis would not 
necessary occur because of DPB and reverse causation, they could reflect a true causal link. 
The fact is that we did not observe such association (see Table 6, particularly the more reliable 
rows showing results for cases with longer fasting times). We made a similar argument for 
timing of blood draw and POPs in section 2.10. 
 
Also concerning DPB: among 177 cases with the available data, tumour stage was not 
associated with any of the three lipid measures; therefore, concentrations of lipids at blood draw 
were not increased by subclinical, more disseminated tumours. 
 
Among only 85 cases with data on tumour grade, cases with less differentiated tumours had 
higher concentrations of triglycerides and TL at study entry than cases diagnosed of more 
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differentiated tumours. There were only 11 cases in the reference category of well differentiated 
tumours. The small numbers do not warrant the conclusion that concentrations of lipids at blood 
draw were already increased by subclinical poorly differentiated tumours. Future studies may 
consider this approach to assessing DPB. 
 
Studies with more complete information on the pancreatic subsite of the tumour may consider 
assessing whether subclinical tumours in different subsites might have altered differently lipids 
and lipophilic substances at blood draw; e.g., because of the pathophysiologic changes that 
ensue when a tumour in the pancreatic head compresses the bile duct (Porta et al., 2005, 
2008a, 2009b). 
 
Cohort studies, nested case-control studies and other longitudinal designs are often most 
efficient to cope with DPB (Porta et al., 2014). However, biases associated with disease 
progression still need to be assessed in such studies (Porta et al., 2009b). First, because in 
some cohort studies the interval between blood draw and outcome is short for at least a subset 
of cases (Dorgan et al., 1999; Hunter et al., 1997; Wolff et al., 1993). Second, because such 
designs sometimes suffer from selection biases due to partial availability of blood samples or 
limited retrieval of disease-related samples (e.g., tumour tissue) (Porta, 2001). And third, 
because they may not have collected relevant etiologic data. Therefore, the empirical tests of 
DPB reported here are relevant beyond the present study. 
 
We used a classification of diagnostic basis that will be useful to perform future etiologic 
analyses on POP concentrations and risk of pancreatic cancer stratified on diagnostic basis, as 
a proxy for diagnostic certainty; these analyses are sometimes referred to as sensitivity 
analyses. Over 75% of cases had been diagnosed through microscopic methods, which is a 
common figure in large studies and case series (Porta, 2005; Porta et al., 1994). Significant 
differences in the percentage of cases with microscopic confirmation were observed across 
countries (>95% of cases from Denmark and Umeå, <40% in other countries). Microscopic 
confirmation was higher in men, and in younger and more educated cases. It was not related to 
tumour subsite or stage, neither to other potentially important variables as BMI, smoking, 
alcohol, or physical activity. Thus, assessing potential biases due to diagnostic certainty and 
disease misclassification will be warranted in etiologic analysis not only as a general precaution, 
but also because diagnostic certainty could be related to exposures associated with factors as 
age, gender, or education (Porta, 2005). 
 
Finally, exposure to the POPs selected for analysis was quite widespread in the study 
population, with substantial variability. This is a main strength of studies within EPIC (Riboli et 
al., 2002). All 22 POPs analysed were detected in some participants, and the lowest number 
detected in one person was 15. We detected and quantified 16 compounds (all but 6) in more 
than 90% of individuals. 42% of participants had one or more of such 16 prevalent POPs at 
concentrations (corrected by TL) above their respective P90. In a study based on the general 
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population of Catalonia (N = 919) (Porta et al., 2012), the corresponding figure was 32% (with 8 
most prevalent POPs out of 19 POPs analysed). In a study based on the US general population 
(N >4,000) (Pumarega et al., 2016), the corresponding figure was 67%, in part, probably, 
because the number of POPs analysed was higher (37 most prevalent POPs out of 91 POPs 
analysed). For participants in the present study and in the studies in Catalonia and the US, the 
geometric mean of the nPhc (TL-corrected POPs; nPhc cut-off: P90) was 2.8, 2.0 and 3.4, 
respectively. 
 
The observed correlations between pairs of POPs were expected (Gasull et al., 2012; Porta et 
al., 2008a, 2012). Correlations among certain POPs are often strong worldwide; it is a feature of 
human contamination by POPs that many studies must address, and so will ours.  
 
Significant differences in plasma concentrations of several POPs (uncorrected and corrected by 
total lipids) were observed by age, sex, BMI, fasting status, and country. They will need to be 
considered in the subsequent analyses on POPs and pancreatic cancer risk. 
 
Participants from Spain had the highest concentrations of p,p’-DDT, β-HCH, PCBs 183 and 187, 
and particularly of HCB, as also observed in previous studies (Aylward et al., 2014). Germany 
had the highest concentrations of some PCBs. Analyses of predictors of POP concentrations in 





The present article not only summarizes the main methodological features of the study, but it 
also reports a number of associations among study and subjects’ characteristics that may play 
important roles in the forthcoming analyses on the association between plasma concentrations 
of POPs and pancreatic cancer risk. Notably, there were differences among countries in 
subjects’ characteristics (as age, gender, smoking, lipid and POP concentrations), and in study 
characteristics (as time from blood collection to index date, year of last follow-up, length of 
follow-up, basis of cancer diagnosis, and fasting status). Adjusting for centre and time of blood 
collection, no factors were significantly associated with fasting status. Plasma concentrations of 
lipids were related to age, body mass index, fasting, country, and smoking. Analyses assessing 
disease progression bias suggested it was highly unlikely. The coexistence of differences 
across study centres in some design features and participant characteristics is of relevance to 
other multicentre studies. Associations among subjects’ characteristics and between such 
characteristics and design features may play important roles in the forthcoming analyses on the 
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Figure 1. Proportional distribution of the time from blood collection to index date according to 
countries (N=1,533). 
Footnote: In cases, the index date corresponds to the date of the diagnosis of pancreatic 
cancer, and in controls to the date of cancer diagnosis of the case matched with. 
 
Figure 2. Distribution of plasma concentrations of total lipids (mg/dL) by case-control status 
(N=1,533). 
 
Figure 3. Percentages of detection and quantification of all POPs analysed in plasma samples 
of the 1533 participants included in the study. 
Footnote: The figures inside the bars refer to the percentage of quantification (detected and 
quantified). For compounds with no figure, the corresponding percentage was 100%. 
 
Figure 4. Time from blood collection to index date according to plasma concentrations of total 
lipids and case-control status. 
 
Table 1. Baseline characteristics of study participants according to case-control status. 
 Total Cases Controls   
Characteristic N (%) N (%) N (%) p-value 
a
 
         Total 1533 (100) 513 (33.5) 1020 (66.5)*   
         
Sex       matched  
Men 746 (48.7) 250 (48.7) 496 (48.6)   
Women 787 (51.3) 263 (51.3) 524 (51.4)   
         
Age** (years)       matched  
Mean ± standard deviation 56.8 ± 7.5 56.8 ± 7.5 56.8 ± 7.6   
Median 57.7 57.6 57.7   
         
Birth cohort       matched  
1919-1938 817 (53.3) 271 (52.8) 546 (53.5)  by age  
1939-1945 503 (32.8) 172 (33.5) 331 (32.5)   
1946-1964 213 (13.9) 70 (13.6) 143 (14.0)   
         
Body mass index (kg/m
2
) 
mean ± standard deviation 26.3 ± 4.2 26.5 ± 4.4 26.2 ± 4.1 0.204 
b
 
Underweight (<18.5) 11 (0.7) 4 (0.8) 7 (0.7) 0.891  
Normal weight (18.5-24.9) 611 (40.6) 197 (39.3) 414 (41.2)   
Overweight (25.0-29.9) 647 (43.0) 219 (43.7) 428 (42.6)   
Obese (≥30.0) 236 (15.7) 81 (16.2) 155 (15.4)   
         
Men, mean ± standard deviation 26.6 ± 3.6 26.8 ± 3.6 26.6 ± 3.5 0.535 
b 
Women, mean ± standard deviation 26.0 ± 4.7 26.2 ± 5.0 25.8 ± 4.5 0.262 
b 
         
Education***       0.195  
Less than primary completed 83 (5.5) 29 (5.8) 54 (5.4)   
Primary school completed 529 (35.3) 189 (38.0) 340 (34.0)   
Technical/professional school 398 (26.6) 115 (23.1) 283 (28.3)   
Secondary school 201 (13.4) 73 (14.7) 128 (12.8)   
Longer education 286 (19.1) 92 (18.5) 194 (19.4)   
         
Marital status       0.492  
Single 67 (6.8) 26 (7.9) 41 (6.2)   
Married/living together 783 (79.1) 255 (77.5) 528 (79.9)   
Divorced/separated 73 (7.4) 22 (6.7) 51 (7.7)   
Widowed 67 (6.8) 26 (7.9) 41 (6.2)   
         
Smoking status       <0.001  
Never 650 (42.8) 206 (40.8) 444 (43.8)   
  – 29 – 
Former 472 (31.1) 135 (26.7) 337 (33.3)   
Current 396 (26.1) 164 (32.5) 232 (22.9)   
         
Alcohol intake at recruitment 
(g/day), median 6.4 6.8 6.4 0.640 
c 
Never and former drinkers 141 (9.2) 45 (8.8) 96 (9.4) 0.930  
>0-6 g/day 600 (39.3) 197 (38.6) 403 (39.6)   
>6-18 g/day 363 (23.8) 125 (24.5) 238 (23.4)   
>18 g/day 424 (27.7) 144 (28.2) 280 (27.5)   
         
Men, median 12.4 13.5 12.0 0.370 
c 
Women, median 2.6 2.4 2.6 0.946 
c 
         
Physical activity       0.884  
Active 101 (8.0) 30 (7.1) 71 (8.4)   
Moderately active 587 (46.5) 199 (47.3) 388 (46.1)   
Moderately inactive 361 (28.6) 120 (28.5) 241 (28.6)   
Inactive 214 (16.9) 72 (17.1) 142 (16.9)   
         
 
[ Continued next page ] 
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Table 1, continued. 
 Total Cases Controls   
Characteristic N (%) N (%) N (%) p-value 
a
 
         Total 1533 (100) 513 (33.5) 1020 (66.5)*   
         
Diabetes mellitus       0.011  
No 1323 (95.7) 431 (93.7) 892 (96.7)   
Yes 59 (4.3) 29 (6.3) 30 (3.3)   
         
Exogenous hormones** (women)       matched  
Yes 154 (22.2) 52 (22.7) 102 (21.9)   
No 541 (77.8) 177 (77.3) 364 (78.1)   
         
Fasting status**       matched  
Fasting (>6 hours) 455 (30.1) 152 (30.0) 303 (30.1)   
In between (3-6 hours) 295 (19.5) 102 (20.2) 193 (19.2)   
Non-fasting (<3 hours) 762 (50.4) 252 (49.8) 510 (50.7)   
         
 
* All cases have 2 matched controls, except 6 cases who have 1 matched control. Cases and controls were 
matched by EPIC study centre, sex, age at blood collection, date and time of blood collection, fasting status 
and, for women, use of exogenous hormones. **At blood collection. *** Highest educational level attained. 
Longer education includes university degree. 
a
 Unless otherwise specified, p value derived from Fisher’s exact test (two-tailed). 
b
 Student’s t test (two-tailed). 
c
 Mann-Whitney’s U test (two-tailed). 
 
Table 2. Influence of characteristics of cases on the probability of having a pancreatic cancer 
diagnosed by  
microscopic methods (vs. clinical tests and other). 
  Basis of cancer diagnosis 





and other**      




  OR (95% CI) p-value
b
 
              Total 506 (98.6)  382 (75.5)  124 (24.5)      
              
Sex              
Men 246 (48.6)  204 (82.9)  42 (17.1) <0.001  1.00 - 0.364 
Women 260 (51.4)  178 (68.5)  82 (31.5)   0.76 (0.41-1.39)  
              
Age at diagnosis  
of pancreatic cancer (years) 
             
Median 66.8  65.9  68.7 <0.001 
c
 0.96 (0.92-0.99) 0.021 
           
<60 years 103 (20.4)  85 (82.5)  18 (17.5) 0.014  1.00 - 0.105
d
 
60-69 years 246 (48.6)  191 (77.6)  55 (22.4)   0.50 (0.23-1.11)  
≥70 years 157 (31.0)  106 (67.5)  51 (32.5)   0.47 (0.21-1.07)  
              
Age at blood collection 
(years) 
             
Median 57.7  57.3  60.0 <0.001 
c
 0.95 (0.92-0.99) 0.018 
           
<50 years 73 (14.4)  60 (82.2)  13 (17.8) 0.001  1.00 - 0.389 
50-54 years 117 (23.1)  99 (84.6)  18 (15.4)   0.64 (0.22-1.84)  
55-59 years 137 (27.1)  105 (76.6)  32 (23.4)   0.48 (0.18-1.26)  
≥60 years 179 (35.4)  118 (65.9)  61 (34.1)   0.47 (0.18-1.19)  
              
Birth cohort              
1919-1938 269 (53.2)  187 (69.5)  82 (30.5) 0.004  1.00 - 0.095
d
 
  – 31 – 
1939-1945 168 (33.2)  139 (82.7)  29 (17.3)   1.54 (0.81-2.91)  
1946-1964 69 (13.6)  56 (81.2)  13 (18.8)   1.87 (0.76-4.60)  
              
Body mass index (kg/m
2
)              
Median 25.7  25.8  25.4 0.325 
c
 1.00 (0.93-1.07) 0.955 
           
Underweight (<18.5) 4 (0.8)  3 (75.0)  1 (25.0) 0.746     
Normal weight (18.5-24.9) 195 (39.5)  142 (72.8)  53 (27.2)   1.00 - 0.912
e
 
Overweight (25.0-29.9) 217 (43.9)  166 (76.5)  51 (23.5)   0.88 (0.46-1.69)  
Obese (≥30.0) 78 (15.8)  61 (78.2)  17 (21.8)   1.00 (0.40-2.53)  
              
[ Continued next page ] 
 
Table 2, continued. 
  Basis of cancer diagnosis 





and other**      




  OR (95% CI) p-value
b
 
              Total 506 (98.6)  382 (75.5)  124 (24.5)      
              
Education              
Less than primary 
completed 
29 (5.9)  20 (69.0)  9 (31.0) 0.782  1.00 - 0.387
d
 
Primary school completed 186 (37.8)  143 (76.9)  43 (23.1)   1.31 (0.34-5.09)  
Technical/professional 
school 
114 (23.2)  91 (79.8)  23 (20.2)   1.39 (0.31-6.29)  
Secondary school 72 (14.6)  56 (77.8)  16 (22.2)   1.53 (0.33-7.09)  
Longer education 91 (18.5)  69 (75.8)  22 (24.2)   1.86 (0.38-9.02)  
              
Marital status              
Single 25 (7.8)  20 (80.0)  5 (20.0) 0.114  1.00 - 0.570 
Married/living together 250 (77.6)  167 (66.8)  83 (33.2)   0.37 (0.08-1.68)  
Divorced/separated 21 (6.5)  12 (57.1)  9 (42.9)   0.29 (0.05-1.73)  
Widowed 26 (8.1)  13 (50.0)  13 (50.0)   0.42 (0.07-2.66)  
              
Smoking status              
Never 203 (40.8)  146 (71.9)  57 (28.1) 0.059  1.00 - 0.329 
Former 133 (26.7)  98 (73.7)  35 (26.3)   0.58 (0.28-1.20)  
Current 162 (32.5)  133 (82.1)  29 (17.9)   0.83 (0.40-1.72)  
              
Alcohol intake at recruitment              
Never and former drinkers 45 (8.8)  25 (56.8)  19 (43.2) 0.020  1.00 - 0.269 
>0-6 g/day 197 (38.6)  150 (76.1)  47 (23.9)   1.54 (0.62-3.82)  
>6-18 g/day 125 (24.5)  92 (75.4)  30 (24.6)   0.71 (0.27-1.90)  
>18 g/day 144 (28.2)  114 (80.9)  27 (19.1)   1.16 (0.43-3.11)  
              
Physical activity              
Active 30 (7.2)  25 (83.3)  5 (16.7) 0.007  1.00 - 0.445 
Moderately active 195 (47.1)  127 (65.1)  68 (34.9)   0.54 (0.15-1.91)  
Moderately inactive 119 (28.7)  82 (68.9) 
 
37 (31.1)   0.48 (0.13-1.83)  
Inactive 70 (16.9)  59 (84.3)  11 (15.7)   0.97 (0.22-4.34)  
              
[ Continued next page ] 
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Table 2, continued. 
  Basis of cancer diagnosis 





and other**      
Characteristic N (%)  N (%)  N (%) p-value
a
  OR (95% CI) p-value
b
 
              Total 506 (98.6)  382 (75.5)  124 (24.5)      
              
Diabetes mellitus              
No 424 (93.6)  338 (79.7)  86 (20.3) 0.635  1.00 - 0.347 
Yes 29 (6.4)  22 (75.9)  7 (24.1)   1.82 (0.52-6.29)  
              
Exogenous hormones (women)              
Yes 50 (22.1)  35 (70.0)  15 (30.0) 0.502  1.00 - 0.231 
No 176 (77.9)  112 (63.6) 
 
64 (36.4)   0.51 (0.16-1.62)  
              
Tumour subsite              
Head of pancreas 229 (66.2)  175 (76.4)  54 (23.6) 0.372  1.00 - 0.209 
Body of pancreas 58 (16.8)  47 (81.0)  11 (19.0)   0.76 (0.28-2.06)  
Tail of pancreas 36 (10.4)  27 (75.0)  9 (25.0)   1.11 (0.35-3.57)  
Overlapping 23 (6.6)  21 (91.3)  2 (8.7)   6.38 (1.06-38.3)  
              
Stage of the tumour              
Localised 51 (28.8)  45 (88.2)  6 (11.8) 0.372  1.00 - 0.464 
Metastatic 126 (71.2)  103 (81.7)  23 (18.3)   0.57 (0.13-2.56)  
              
*Microscopic methods: this category includes cases with the following bases of diagnosis as the first basis, sorted from 
higher to lower validity: Autopsy (N=18), Histology of primary tumour (N=144), Histology of metastasis (N=51), 
Histology/Cytology of primary tumour (N=96), Histology/Cytology of metastasis (N=15), and Cytology or haematology 
(N=58). 
**Clinical tests and other: this category includes cases with the following bases of diagnosis as the first basis, sorted 
from higher to lower validity: Specific biochemical or immunological tests (N=4), Exploratory surgery/autopsy (N=4), 
Endoscopy (N=4), Magnetic resonance imaging (N=2), Computerized tomography scan (N=16), Radiological 
examination (N=5), Clinical investigation (N=46), Clinical observation (N=34), Self-report (N=2), Death certificate only 
(N=7). 
OR: Odds ratio adjusted for sex, center, and (except for age at blood extraction and birth cohort) age at diagnosis of 
exocrine pancreatic cancer (EPC). An OR=1 indicates the reference category. An OR>1 indicates a higher probability 
of having the pancreatic cancer diagnosed through microscopic methods. 
a
 Unless otherwise specified, p value derived from Fisher’s exact test (two-tailed). 
b
 Unless otherwise specified, p value derived from Wald’s test. 
c
 Mann-Whitney’s U test (two-tailed). 
d
 Test for linear trend (multivariate analogue of Mantel’s extension test). 
e
 Without participants <18.5 kg/m
2
 of body mass index. 
 
Table 3. Influence of participants’ characteristics on fasting status at blood collection.* 
Characteristic aOR (95% CI) p-value 
    
Sex    
Men 1.00 - 0.291 
Women 0.77 (0.47-1.26)  
    
Age at blood collection (years)    
<50 years 1.00 - 0.868 
50-54 years 0.82 (0.37-1.84)  
55-59 years 0.96 (0.45-2.02)  
≥60 years 1.11 (0.55-2.27)  
    
Birth cohort    
1919-1938 1.00 - 0.506 
1939-1945 0.71 (0.40-1.26)  
1946-1964 0.95 (0.47-1.91)  
  – 33 – 
    
Body Mass Index (kg/m
2
)    
Normal weight (18.5-24.9) 1.00 - 0.313 
Overweight (25.0-29.9) 0.98 (0.57-1.69)  
Obese (≥30.0) 1.63 (0.79-3.39)  
    
Smoking status    
Never 1.00 - 0.918 
Former 1.13 (0.63-2.01)  
Current 1.07 (0.58-1.99)  
    
Alcohol intake at recruitment    
Never and former drinkers 1.00 - 0.637 
>0-6 g/day 0.75 (0.33-1.70)  
>6-18 g/day 0.72 (0.30-1.73)  
>18 g/day 0.56 (0.23-1.36)  
    
Physical activity    
Active 1.00 - 0.487 
Moderately active 1.29 (0.32-5.17)  
Moderately inactive 2.04 (0.49-8.51)  
Inactive 1.63 (0.35-7.60)  
    
Time of blood collection**    
6:00-9:30 1.00 - <0.001 
9:31-11:20 0.26 (0.14-0.47)  
11:21-14:14 0.08 (0.03-0.20)  
14:15-20:00 <0.01 (0.00-0.03)  
Missing 0.06 (0.01-0.23)  
    
 
N = 1,512. 
*Fasting >6 hours vs. fasting ≤6 hours. 
aOR: Adjusted odds ratio. Each variable is adjusted for centre and time of blood collection. 
An OR=1 indicates the reference category 
** 179 of the 192 participants (93%) with missing information on time of blood collection were from the Umeå study 
centre. 165 of such 179 participants from Umeå (92%) had been fasting for >6 hours, a fact that explains why time 
of blood collection was less frequently recorded in this centre. All other participants (i.e., participants with available 
information on time of blood collection, N = 1,320) were distributed among quartiles of time of blood collection. 
When time of blood collection is not adjusted for study centre, the OR for the missing category is 5.2, a figure that 




Table 4. Influence of participants’ characteristics on total lipid concentrations (mg/dL). 
Characteristic aGM (95% CI) p-value 
    
Case-control status    
Controls (Ref.) 642 (634-650)  
Cases 647 (636-658) 0.441 
    
Country    
Denmark (Ref.) 635 (621-649)  
Sweden 736 (711-762) <0.001 
Germany 631 (614-649) 0.736 
United Kingdom 639 (619-659) 0.747 
The Netherlands 642 (620-666) 0.549 
Italy 643 (618-668) 0.637 
Spain 585 (563-609) 0.001 
Greece 587 (562-612) 0.001 
France 598 (553-646) 0.145 
Norway    
    
Sex    
Men (Ref.) 647 (638-657)  
  – 34 – 
Women 640 (631-650) 0.336 
    
Age at blood collection (years)    
<50 years (Ref.) 609 (592-626)  
50-54 years 632 (619-646) 0.036 
55-59 years 649 (637-662) <0.001 
≥60 years 662 (651-673) <0.001 
    
Birth cohort    
1919-1938 (Ref.) 659 (650-668)  
1939-1945 635 (624-646) 0.001 
1946-1964 608 (591-626) <0.001 
    
Body Mass Index    
Normal weight (Ref.) 617 (608-627)  
Overweight 656 (646-666) <0.001 
Obese 685 (667-702) 0.005 
    
Smoking status    
Never (Ref.) 637 (627-646)  
Former 640 (628-651) 0.689 
Current 661 (648-674) 0.004 
    
Alcohol intake at recruitment    
Never and former drinkers 652 (629-675)  
>0-6 g/day 635 (624-646) 0.193 
>6-18 g/day 637 (624-650) 0.262 
>18 g/day 660 (647-673) 0.550 
    
Physical activity    
Active (Ref.) 619 (595-643)  
Moderately active 636 (626-647) 0.203 
Moderately inactive 633 (620-646) 0.310 
Inactive 639 (622-657) 0.185 
    
Fasting status    
Fasting (>6 hours) (Ref.) 616 (598-635)  
In between (3-6 hours) 662 (646-678) 0.001 
Non-fasting (<3 hours) 654 (642-666) 0.005 
    
 
aGM: Geometric mean adjusted for sex, age (except for birth cohort), body mass index, fasting status, and centre (except 
for country). N = 1,487. 
p-value: p-value of each category of the variable when compared with the reference group (Ref.). 
 
Table 5. Plasma concentrations of POPs (pg/mL) detected in over 90% of study participants according to 
sociodemographic characteristics.* 
 
        
Characteristics p,p’-DDT p,p’-DDE Oxychlordane Trans-
nonachlor 
HCB β-HCH PCB 118 PCB 156 
         
All participants 
 
86 (48 - 
166) 
3371 (1728 - 
6700) 
55 (38 - 82) 74 (48 - 
122) 
393 (253 - 
790) 
355 (201 - 
671) 
151 (98 - 
233) 
122 (83 - 
171) GM and P90 94 (381) 3384 (12733) 56 (120) 76 (189) 50  (2459) 386 (1467) 149 (343) 16 (233) 
         
Detected (%) 99.7 100 99.8 100 100 99.9 100 100 
Quantified (%) 97.8 99.8 92.2 100 100 99.9 100 100 
Non-
quantified (%) 
1.9 0.2 7.6 0 0 0.0 0 0 
Non-detected 
(%) 
0.3 0 0.2 0 0 0.1 0 0 
         
Gender         
Male 82 (46 - 
157) 
3312 (1667 - 
6483) 
55 (38 - 82) 86 (55 - 
143) 
349 (233 - 
646) 
284 (176 - 
540) 
144 (95 - 
229) 
141 (94 - 
190) Female 87 (49 - 
171) 
3 25 (1835 - 
6947) 
56 (37 - 82) 6  (42 - 
100) 
451 (266 - 
929) 
424 (233 - 
795) 
156 (99 - 
234) 
09 (77 - 
151) p-value 0. 38 0.348 0.961 < .001 <0.001 <0.001 0.171 <0.001 
         Age at blood 
collection 
        
<50 years 88 (48 - 
146) 
3135 (1677 - 
5774) 
40 (28 - 61) 49 (32 - 
73) 
306 (184 - 
682) 
287 (144 - 
544) 
119 (77 - 
175) 
94 (64 - 
136) 50-54 years 60 (35 - 
107) 
2402 (1371 - 
4421) 
50 (35 - 70) 1 (49 - 
104) 
343 (237 - 
537) 
262 (157 - 
440) 
31 (89 - 
208) 
2  (90 - 
172) 55-59 years 82 (49 - 
177) 
3170 (1693 - 
6996) 
57 (39 - 84) 8  (54 - 
130) 
398 (268 - 
708) 
332 (207 - 
621) 
15  (101 - 
237) 
31 (89 - 
180) ≥60 years 13 (63 - 
212) 
4419 (2293 - 
8735) 
67.5 (46 - 
102) 
86 (53 - 
145) 
512 (296 - 
992) 
508 (270 - 
928) 
174 (111 - 
265) 
3  (85 - 
176) p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
         
Birth cohort         
1919-1938 103 (59 - 
207) 
4087 (2121 - 
8226) 
65 (45 - 99) 87 (54 - 
146) 
485 (286 - 
946) 
456 (249 - 
843) 
174 (112 - 
265) 
133 (90 - 
180) 
  – 35 – 
1939-1945 66 (38 - 
119) 
2563 (1437 - 
4949) 
50 (36 - 72) 70 (49 - 
103) 
340 (239 - 
549) 
270 (174 - 
446) 
134 (91 - 
203) 
123 (89 - 
172) 1946-1964 82 (43 - 
142) 
277  (1448 - 
5635) 
38 (25 - 57) 46 (32 - 
68) 
312 (167 - 
797) 
290 (129 - 
565) 
114 (70 - 
171) 
8  (57 - 
129) p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
         Body Mass 
Index 
        
Normal range 68 (41 - 
117) 
2772 (1515 - 
5128) 
52 (36 - 74) 69 (42 - 
108) 
310 (216 - 
536) 
285 (168 - 
519) 
137 (87 - 
204) 
125 (88 - 
172) Overweight 95 (54 - 
183) 
3766 (1974 - 
7077) 
57 (39 - 87) 78 (50 - 
131) 
440 (278 - 
845) 
382 (213 - 
708) 
159 (106 - 
244) 
26 (87 - 
174) Obese 40 (76 - 
382) 
5 89 (2625 - 
11334) 
63 (44 - 
106) 
81 (53 - 
143) 
76  (408 - 
3182) 
599.5 (333 - 
1197) 
18  (121 - 
284) 
08 (71 - 
162) p-value <0.001 <0.001 < .001 <0.001 <0.001 <0.001 <0.001 0.010 
         
Fasting status         
Fasting (>6 
hours) 
99 (56 - 
216) 
4216 (2076 - 
8243) 
57 (40 - 85) 78 (51 - 
127) 
356 (242 - 
999) 
358 (145 - 
896) 
179 (117 - 
264) 
124 (90 - 
170) In between (3-6 
hours) 
83 (48 - 
197) 
3511 (1640 - 
7732) 




3 3 (233 - 
821) 
149 (91 - 
235) 
27 (82 - 
179) N n-fasting (<3 
hours) 
7  (45 - 
135) 
2923 (1576 - 
5680) 




33  (207 - 
555) 
1 8 (88 - 
203) 
20 (82 - 
168) p-val e <0.001 <0.001 0.192 0.011 0.010 0.002 <0.001 0.357 
         
 





Country         
Denmark 57 (37 - 
89) 
2110 (1142 - 
3714) 
63 (45 - 
93) 
106 (69 - 
157) 
350 (264 - 
472) 
244 (182 - 
332) 
144 (91 - 
207) 
139 (103 - 
179) Sweden 63 (39 - 
91) 
2509 (1455 - 
4360) 
57 (41 - 
85) 
0  (68 - 
149) 
260 (195 - 
334) 
143 (98 - 
236) 
173 (117 - 
255) 
45 (106 - 
189) Germany 162 (79 - 
336) 
5272 (2467 - 
10526) 
43 (32 - 
63) 
59 (41 - 
83) 
743 (483 - 
1183) 
40  (261 - 
697) 
172 (123 - 
262) 
6  (132 - 
246) United 
Kingdom 
7  (50 - 
124) 
3 94 (1935 - 
5447) 
44 (32 - 
61) 
54 (39 - 
82) 
237 (166 - 
338) 
484 (324 - 
717) 
116 (76 - 
172) 
75 (61 - 99) 
The 
Netherlands 
88 (53 - 
134) 
33  (1844 - 
5192) 
 (45 - 
85) 
51 (35.5 - 
75) 
552 (296 - 
859) 
394 (216 - 
546) 
39 (93 - 
210) 
114 (83 - 
148) Italy 52 (89 - 
258) 
804 (3497 - 
10297) 
0 (59 - 
124) 
80 (54 - 
121) 
627 (342 - 
922) 
629 (408 - 
988) 
2  (123 - 
316) 
22 (93 - 
156) Spain 311 (156 - 
558) 
9538 (4616 - 
15256) 
44 (33 - 
59) 




23 7 (1317 - 
3881) 
190 (134 - 
277) 
88 (59 - 
136) Greece 23  (117 - 
470) 
1998 (6790 - 
23723) 
46 (31 - 
100) 
53 (26 - 
127) 
218  (904 - 
4387) 
1424 (676 - 
2484) 
81 (55 - 
121) 
31 (21 - 54) 
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
         
*The concentrations are expressed in median (percentile 25-percentile 75) pg/mL (pg/mL: parts per trillion, ppt). The second row for all 
participants presents the geometric mean (GM) and the 90th percentile (P90). p-value for Kruskal-Wallis test (two tailed). 
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Table 5, continued. 
 
        
Characteristics PCB 138 PCB 153 PCB 
180 
PCB 74 PCB 99 PCB 170 PCB 183 PCB 187 
         
All participants 
 






66 (45 - 
97.5) 















73 (167) 188 
(406)          
Detected (%) 100 100 100 100 99.8 100 99.9 100 
Quantified (%) 100 100 100 99.9 99.5 100 99.6 100 
Non-
quantified (%) 
0 0 0 0.1 0.3 0 0.3 0 
Non-detected 
(%) 
0 0 0 0 0.2 0 0.1 0 
         
Gender         






63 (41 - 
91) 




86 (57 - 
126) 
224 (151 
- 333) Female 58  (376 - 
838) 




70 (48 - 
102) 




68 (42 - 
98) 
164 (107 
- 233) p-value <0.001 <0.001 <0.001 < .001 < .001 <0.001 <0.001 <0.001 
         Age at blood 
collection 
        
<50 years 544 (359 - 
769) 




54 (34 - 
72) 




71 (46 - 
106) 
166 (106 




83  (610 
- 1160) 
58 (41 - 
81) 




75 (49 - 
110) 
190 (133 






68 (47 - 
95) 




74 (50 - 
117) 
200 (133 
- 289) ≥60 years 655 (448 - 
981) 




81 (52 - 
113) 




79 (52 - 
115) 
195 (130 
- 286) p-value <0.001 <0. 01 <0.001 <0.001 <0.001 <0.001 0.254 0.012 
         
Birth cohort         







78 (52 - 
108) 




80 (54 - 
118) 
203 (136 - 







58 (42 - 
81) 




73 (49 - 
110) 
18  (130 






50 (29 - 
71) 




66 (38 - 
98) 
155 (98 - 
233) p-value <0.001 <0. 01 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
         Body Mass 
Index 
        







64 (43 - 
93) 
68 (44 - 
101) 
372 (268 - 
509) 
73 (47 - 
105) 
186 (125 





83  (591 
- 1170) 
68 (46 - 
100) 
73 (50 - 
113) 
382 (264 - 
532) 
78 (54 - 
117) 
197 (136 







72 (52 - 
107) 
80 (49 - 
121) 





- 311) p-value .054 0.213 0.102 .006 0.008 .154 0.0 5 0.039 
         
Fasting status         
Fasting (>6 
hours) 







67 (45 - 
99) 




90 (65 - 
128) 
234 (159 
- 341) In between (3-6 
hours) 





836 ( 68 
- 1159) 
66 (46 - 
101) 




68 (43 - 
109) 
182 (123 
- 261) N n-fasting (<3 
hours) 
60  (404 - 
873) 
986 (660 
- 1 99) 
758 (541 
- 1075) 
66 (44 - 
96) 
69 (44 - 
100) 
3 5 (244 
- 501) 
69 (46 - 
103) 
171 (112 
- 248) p-val e <0.001 <0.001 <0.001 0.517 < .001 0. 09 < .001 <0.001 
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Country         






61 (45 - 
84) 




70 (49 - 
99) 
200 (148 




90  (693 
- 1215) 
60 (40 - 
82) 




8 (71 - 
142) 
250 (186 







7  (53 - 
105) 




98 (67 - 
135) 
204 (149 
- 311) United 
Kingdom 
383 (282 - 
528) 




79 (54 - 
110) 




46 (33 - 
65) 
12  (90 - 
160) The 
Netherlands 
619 (420 - 
789) 




70 (46 - 
105) 




73 (49 - 
97) 
39 (94 - 




8 8 (683 
- 1149) 
94 (64 - 
121) 




84 (59 - 
116) 
95 (136 






74 (50 - 
109) 




09 (78 - 
167) 
362 (251 
- 575) Greece 224 (147 - 
388) 




29 (18 - 
39) 




29 (18.5 - 
55) 
76 (45 - 
139) p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
         
*The concentrations are expressed in median (percentile 25-percentile 75) pg/mL (pg/mL: parts per trillion, ppt). The 
second row for all participants presents the geometric mean (GM) and the 90th percentile (P90). p-value for Kruskal-




Table 6. Influence of total lipid concentrations of pancreatic cancer cases 
on the time from blood collection to cancer diagnosis (years), in all cases 
and stratified by fasting status. 
    
Time from blood 
draw to diagnosis 
 
Total lipid concentrations N (%)  aGM (95% CI) p-value 
       Total lipids (mg/dL)* 495 (96.5)     
<565.0 126 (25.5)  7.4 (6.8-8.0)  
565.0-635.7 123 (24.8)  8.3 (7.7-9.0) 0.026 
635.8-733.0 126 (25.5)  8.7 (8.1-9.3) 0.003 
≥733.0 120 (24.2)  8.6 (7.9-9.2) 0.009 
       
Total lipids (mg/dL)       
of cases in fasting status <3 hours 246 (49.7)     
<565.0 70 (28.5)  6.7 (6.1-7.3)  
565.0-635.7 58 (23.6)  8.4 (7.6-9.3) 0.001 
635.8-733.0 58 (23.6)  7.8 (7.1-8.7) 0.026 
≥733.0 60 (24.4)  8.5 (7.6-9.4) 0.001 
       
Total lipids (mg/dL)       
of cases in fasting status between 
3 and 6 hours 99 (20.0)     
<565.0 24 (24.2)  7.1 (6.1-8.3)  
565.0-635.7 26 (26.3)  8.2 (7.1-9.6) 0.191 
635.8-733.0 29 (29.3)  7.8 (6.8-9.0) 0.386 
≥733.0 20 (20.2)  7.9 (6.7-9.4) 0.379 
       
Total lipids (mg/dL)       
of cases in fasting status ≥6 hours 150 (30.3)     
<565.0 32 (21.3)  9.2 (7.6-11.1)  
565.0-635.7 39 (26.0)  8.3 (7.1-9.8) 0.434 
635.8-733.0 39 (26.0)  10.4 (8.8-12.2) 0.364 
≥733.0 40 (26.7)  9.7 (8.3-11.4) 0.685 
       
 
aGM: Geometric mean of the time from blood collection to the diagnosis of pancreatic 
cancer adjusted for age, sex, body mass index, and centre. 
* further adjusted for fasting status. 
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Table 7. Influence of tumour characteristics on total cholesterol, triglycerides and total lipids 
concentrations (mg/dL). 
Multivariate General Linear Models. 
 Total Total cholesterol  Triglycerides  Total lipids 
Tumour 
characteristic 
N (%) aGM (95% CI) p-
value 
 aGM (95% CI) p-
value 




              
Stage of the 
tumour (N = 168) 
        
 
   
 
Localised 50 (29.8) 186 
(175-
199) 
  114 
(94-
139) 




Metastatic 118 (70.2) 200 
(193-
207) 
0.090  119 
(107-
132) 




              
Grade of the 
tumour (N = 84) 
             
Well 
differentiated 
11 (13.1) 174 
(156-
194) 






44 (52.4) 182 
(172-
192) 
0.483  117 
(100-
136) 






29 (34.5) 190 
(178-
203) 
0.182  130 
(108-
157) 






   0.151    0.006    0.030  
              
Tumour subsite (N 
= 339) 
             
Head of pancreas 223 (65.8) 200 
(195-
204) 
  125 
(118-
134) 




Body of pancreas 58 (17.1) 195 
(186-
204) 
0.367  118 
(104-
134) 




Tail of pancreas 35 (10.3) 199 
(188-
211) 
0.953  130 
(110-
153) 




Overlapping 23 (6.8) 190 
(177-
204) 
0.212  96 
(78-
118) 




              
 
aGM: Geometric mean, in each of the 9 models adjusted for age, sex, body mass index, fasting status, 
and repository. 
p-value: p-value of each category of the variable when comparing with the reference group. 
p-trend: p-value derived from multivariate analogue of Mantel’s extension test for linear trend. 
 


















Time from blood collection to index date (years)
Sweden
Denmark 
Rest of EPIC countries











250 500 750 1000 1250 1500 1750
Controls
Median:  633 mg/dL
Cases
















































(N=269) (N=128) (N=249) (N=128) (N=269) (N=129) (N=233) (N=128)


































Quartiles of plasma concentrations of total lipids  
 
  






• There are unique methodological issues for research on environmental causes of human diseases. 
 
• Through innovative methods, the study addressed some of such issues. 
 
• Analyses assessing disease progression bias suggested it was unlikely in this study. 
 
• Exposure to POPs was widespread in the study population, with substantial variability. 
 
• Lipids were influenced by differences in study design across participating centres. 
 
• Differences across study centres in some design features and participant characteristics are relevant for other 
multicentre studies.  
 
 
 
 
 
 
